Asymmetry Capital Management L.P. cut its stake in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 30.4% during the first quarter, HoldingsChannel.com reports. The firm owned 31,304 shares of the specialty pharmaceutical company’s stock after selling 13,672 shares during the quarter. Jazz Pharmaceuticals makes up approximately 5.9% of Asymmetry Capital Management L.P.’s portfolio, making the stock its 4th largest holding. Asymmetry Capital Management L.P.’s holdings in Jazz Pharmaceuticals were worth $4,727,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in JAZZ. US Bancorp DE raised its position in shares of Jazz Pharmaceuticals by 49.5% during the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after purchasing an additional 360 shares during the period. We Are One Seven LLC acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $157,000. Financial Gravity Companies Inc. raised its position in shares of Jazz Pharmaceuticals by 124.6% during the first quarter. Financial Gravity Companies Inc. now owns 1,271 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 705 shares during the period. Brighton Jones LLC acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter worth $205,000. Finally, Invictus RG acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $206,000. 90.62% of the stock is currently owned by institutional investors.

Shares of Jazz Pharmaceuticals opened at $161.24 on Thursday, Marketbeat Ratings reports. Jazz Pharmaceuticals has a 1-year low of $160.05 and a 1-year high of $163.09. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The firm has a market cap of $9.96 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The firm had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. equities research analysts anticipate that Jazz Pharmaceuticals will post 11.65 EPS for the current year.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 877 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $139.62, for a total value of $122,446.74. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Karen J. Wilson sold 3,760 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $165.00, for a total value of $620,400.00. Following the completion of the transaction, the senior vice president now owns 15,811 shares in the company, valued at approximately $2,608,815. The disclosure for this sale can be found here. Insiders sold 20,837 shares of company stock worth $3,200,686 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

A number of equities research analysts have recently issued reports on the company. Piper Jaffray reaffirmed a “buy” rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, March 1st. HC Wainwright set a $160.00 target price on Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, May 9th. ValuEngine lowered Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Seaport Global Securities set a $175.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 6th. Finally, Mizuho reaffirmed a “hold” rating and set a $150.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 9th. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $181.60.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.